Tests VS-7375 alone and with cetuximab in KRAS G12D pancreatic cancer
Tests the oral drug VS-7375, alone or with cetuximab, in adults with metastatic pancreatic cancer.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Key facts
- Where
- Ann Arbor, Baltimore, Boston, Chapel Hill, Charlottesville, Chicago, Coral Springs, East Brunswick, Fairfax, Fort Worth, Grand Rapids, Houston, Jacksonville, Los Angeles, Madison, Nashville, New York, Rochester, San Antonio, Seattle, St Louis, Tamarac, Tampa, and West Valley City, United StatesSee the 27 sites
- Phase
- Phase 2
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- Johns Hopkins UniversityBaltimore, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- University of North CarolinaChapel Hill, United StatesTaking people
- UVA HealthCharlottesville, United StatesTaking people
- University of ChicagoChicago, United StatesTaking people
- BRCR Global - Coral SpringsCoral Springs, United StatesTaking people
- START - New JerseyEast Brunswick, United StatesTaking people
- Virginia Cancer SpecialistsFairfax, United StatesTaking people
- START DallasFort Worth, United StatesTaking people
- START | MidwestGrand Rapids, United StatesTaking people
- MD Anderson Cancer CenterHouston, United StatesTaking people
- Mayo Clinical FloridaJacksonville, United StatesTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesTaking people
- START - Los AngelesLos Angeles, United StatesTaking people
- Valkyrie Clinical TrialsLos Angeles, United StatesTaking people
- UW HealthMadison, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
- NYU-ManhattanNew York, United StatesTaking people
- Mayo Clinical RochesterRochester, United StatesTaking people
- START | San AntonioSan Antonio, United StatesTaking people
- Virginia MasonSeattle, United StatesTaking people
- Washington UniversitySt Louis, United StatesTaking people
- BRCR Global- TamaracTamarac, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
- START Mountain RegionWest Valley City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Verastem, Inc.
- Trial code
- NCT07644559
- Record updated
- 6 November 2026
- Original description
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic CancerRead full original descriptionShow less
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Inclusion: Histologic or cytologic confirmed PDAC; Measurable disease per RECIST 1.1; Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing); ECOG PS=0 or 1; Adequate organ function; VS-7375 + cetuximab (2L PDAC) :; -Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months; VS-7375 + cetuximab (1L PDAC) :; -Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease.
Exclusion: Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter; Major surgery within 4 weeks of first treatment dose; Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose; Receipt of prior direct RAS inhibitor; Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter; Inability to swallow oral medication; History of drug-induced Interstitial Lung Disease; Have any documented co-existing pathogenic or likely pathogenic RAS mutation(s) in KRAS; Untreated or symptomatic CNS metastasis; Receipt of PPI, P-CABs, or H2 blocker within 5 days; Other protocol-defined inclusion/exclusion criteria may apply.